Last updated: March 9, 2026
What Is NDC 50383-0802?
NDC 50383-0802 refers to Kybella (deoxycholic acid), a treatment designed to reduce submental fat (double chin). It was approved by the U.S. Food and Drug Administration (FDA) in 2015. The drug is administered via multiple injections and marketed primarily for aesthetic procedures targeting contour irregularities.
Market Overview
Market Size
- Global aesthetic injection market: Valued at approximately $4.4 billion in 2022, with a compound annual growth rate (CAGR) of 9.2% from 2022 to 2028.
- U.S. market share: Accounts for roughly 60% of global aesthetic procedures, with an estimated $2.6 billion in 2022.
- Kybella's share: Estimated to capture 15-20% of the submental fat reduction segment, which is projected to grow at a CAGR of 8% in the near term.
Key Competitors
- Surgical options: Liposuction remains dominant but declining with non-invasive preferences.
- Injectable alternatives:
- Dysport, Botox: Primarily used off-label; not direct competitors but impacting market dynamics.
- CoolSculpting (non-invasive fat reduction): Estimated global revenue of around $1.2 billion in 2022.
Adoption and Usage Trends
- Increasing acceptance of minimally invasive procedures.
- Rising demand among middle-aged adults and younger demographics.
- Growing urban cosmetic market and self-pay insurance models.
Price Analysis
Current Pricing
- Per treatment cost: $1,200–$1,800, depending on geographic location and provider.
- Treatment protocol: Typically requires 2–4 sessions, each involving 20–50 injections.
- Average total cost per patient: $3,000–$6,000.
Cost Factors
- Drug acquisition price: Approximately $400–$600 per vial.
- Vial usage: 6–8 vials per treatment session.
- Provider markup: Typically adds 30-50% to raw drug cost.
Price Trends
- Slight price decreases due to increased competition and manufacturing efficiencies.
- Insurance reimbursement is rare; most treatments are out-of-pocket.
Future Price Projections
Short-Term (Next 1–2 years)
- Price stabilization: Slight decrease expected, averaging around $1,100–$1,500 per treatment for providers.
- Market penetration: Expansion into new markets (Asia, Europe) may influence price adjustments.
Mid to Long-Term (3–5 years)
- Potential price reduction: As biosimilar or alternative formulations develop, prices could decline by 10–20%.
- Premiumization trend: Some providers may charge a premium for specialized care, maintaining higher costs in certain markets.
Factors Influencing Price Dynamics
- Regulatory changes: Potential FDA or international approvals for similar compounds.
- Manufacturing capacity: Increased production efficiency may lower cost.
- Competitive landscape: Entry of biosimilar or competing products could pressure prices downward.
- Market growth: Increased adoption, especially in emerging markets, may sustain current prices longer.
Investment and R&D Considerations
- Manufacturers are exploring combinations with other aesthetic agents.
- Pipeline developments aim to extend indications beyond submental fat, potentially impacting pricing strategies.
- Market entrants with lower-cost production could disrupt current pricing.
Summary of Market and Price Outlook
| Aspect |
Current Status |
Future Outlook |
| Market size |
$2.6 billion (U.S.), growing rapidly |
Continued expansion, CAGR ~8–10% |
| Treatment cost |
$1,200–$1,800 per session |
Stabilizes or slightly decreases |
| Price drivers |
Provider markups, drug cost |
Biosimilar development, market saturation |
| Competitive landscape |
Limited in aesthetic fat reduction |
Entry of biosimilars, new formulations |
Key Takeaways
- The market for submental fat reduction, dominated by Kybella, is expanding rapidly alongside the broader aesthetic injection trend.
- Current treatment prices are stable, with incremental declines projected as competition and manufacturing efficiencies increase.
- Adoption rates in emerging markets will influence global pricing and market size.
- Biosimilar and alternative product development remain primary risks to price stability.
- Regulatory and technological innovations could alter the competitive landscape and pricing strategies.
FAQs
Q1: What is the expected annual growth rate for Kybella’s market segment?
Answer: Approximately 8%–10%, driven by increasing demand for minimally invasive aesthetic treatments.
Q2: How does Kybella’s pricing compare globally?
Answer: It varies based on market development, but treatment costs generally range from $1,100 to $1,800 per session internationally.
Q3: Are there upcoming biosimilars or alternatives expected to impact prices?
Answer: Yes; biosimilar candidates and other non-invasive fat reduction technologies are under development and could influence prices within 3–5 years.
Q4: What factors could lead to a significant shift in Kybella’s pricing strategy?
Answer: Regulatory approval of new competitors, improvements in manufacturing, or changes in reimbursement policies.
Q5: How will expanding markets in Asia influence overall market size?
Answer: Larger populations and rising aesthetic awareness could increase market size by 10–15% over the next five years.
References:
[1] Grand View Research. (2023). Aesthetic Medicine Market Analysis.
[2] Frost & Sullivan. (2022). Global Non-Invasive Fat Reduction Market Forecast.
[3] U.S. FDA. (2015). Kybella (deoxycholic acid) FDA approval documentation.
[4] Statista. (2022). Cosmetic Procedures Market Revenue Data.
[5] BioSpace. (2023). Biosimilar Development Trends in Aesthetic Medicine.
